COMMUNIQUÉS West-GlobeNewswire

Communiqué de presse: Sanofi annonce sa décision de ne pas soumettre l’amlitélimab dans la dermatite atopique à des évaluations réglementaires mondiales
24/07/2026
Sanofi annonce sa décision de ne pas soumettre l’amlitélimab dans la dermatite atopique à des évaluations réglementaires mondiales Paris, le 24 juillet 2026. Sanofi a annoncé aujourd’hui l’arrêt du développement [...]
Ipsen provides update on Phase III BOLD trial in biliary atresia
24/07/2026
PARIS, FRANCE, 24 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III BOLD trial evaluating Bylvay versus placebo for patients living with biliary atresia (BA) who have already undergone a [...]
Ipsen fait le point sur l'essai de Phase III BOLD dans l'atrésie des voies biliaires
24/07/2026
PARIS, FRANCE, 24 JUILLET 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) a annoncé aujourd’hui que l'essai de Phase III BOLD, évaluant Bylvay versus placebo chez des patients atteints d'atrésie des voies biliaires (AVB) ayant [...]
Codexis Announces Pricing of Public Offering of Common Stock
24/07/2026
REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today [...]
SodaSlim Capsule Label Guide: What the Supplement Facts Panel, Serving Directions, and Safety Statements Disclose for 2026
24/07/2026
SodaSlim's Caffeine Anhydrous, Green Tea Extract, Garcinia, Raspberry Ketone, and Green Coffee Bean Extract Amounts and Sourcing Ogden, UT, July 23, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated by [...]
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
24/07/2026
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed [...]
Core Axis Introduces Science-Driven Supplement Protocol Developed Specifically for Hashimoto's Thyroiditis
24/07/2026
Cheyenne, Wyoming, July 23, 2026 (GLOBE NEWSWIRE) -- Core Axis , a health brand founded by MC Bio-Logic LLC, announces the upcoming launch of its daily supplement protocol developed with Hashimoto's thyroiditis in mind [...]
Crescent Biopharma Announces Grants of Inducement Awards
23/07/2026
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
23/07/2026
Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026 Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per [...]
Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report
23/07/2026
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended June 30, 2026 [...]
The Joint Corp. to Report 2026 Second Quarter Results on Thursday, August 6 and Host Conference Call and Webcast
23/07/2026
SCOTTSDALE, Ariz., July 23, 2026 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of chiropractic care through The Joint Chiropractic ® network, announced it will report its 2026 [...]
Codexis Announces Proposed Public Offering of Common Stock
23/07/2026
REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today [...]
Cytokinetics to Announce Second Quarter Results on August 6, 2026
23/07/2026
SOUTH SAN FRANCISCO, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 6, 2026 at 4:00 PM Eastern Time. [...]
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
23/07/2026
Media Release COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026 Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE ® DLBCL-1 trial and was not met Genmab A/ [...]
CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026
23/07/2026
MINNEAPOLIS, July 23, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026
23/07/2026
LEXINGTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]
Heartflow to Report Second Quarter 2026 Financial Results on August 13, 2026
23/07/2026
SAN FRANCISCO, July 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the [...]
HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K
23/07/2026
Company believes proposed Fortitude merger represents a significant opportunity for the Company’s shareholders; preliminary proxy statement in connection with the Proposed Transaction expected to be filed shortly, with [...]
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
23/07/2026
-- FDA clearance of the IND, together with the previously cleared CTA, establishes a global Phase 1/2 clinical program for PM577a -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing [...]

Pages